Biocomposites to host industry symposium and present new STIMULAN® data at EBJIS-MSIS 2026

/in

Industry symposium to explore local delivery of combination antibiotics across spine and arthroplasty Poster showcases the efficacy of STIMULAN® calcium sulfate beads, loaded with a combination of Gram-positive and Gram-negative antibiotics, against S. aureus biofilms Keele, UK, 9 September 2026 – Biocomposites, an international medical devices company that engineers, manufactures and markets world-leading products for […]

Read more

Simris Group confirms strategic direction and advances two amanitin-based ADC programs toward the clinic

/in

Simris Group AB (publ) (“Simris” or the “Company”) confirms its strategy to develop amanitin-derived novel payloads to overcome treatment resistance in both liquid and solid tumors. Under strengthened specialist leadership, the Company will focus on advancing two proprietary Antibody-Drug Conjugate (“ADC”) programs into clinical development by late 2027 or early 2028. Read more…

Read more

Novo Nordisk Foundation – New Copenhagen facility to strengthen Europe’s quantum manufacturing capabilities

/in

The state-of-the-art quantum facility will strengthen Europe’s ability to design, manufacture and scale next-generation quantum chips, helping to position the continent as a global leader in quantum technology. Today, Quantum Foundry Copenhagen and the Novo Nordisk Foundation announce plans to establish a new 5,300 m² quantum chip fabrication facility in Copenhagen. The facility will develop […]

Read more

Poolbeg Pharma to Participate in Key Conferences in September 2026

/in

Poolbeg Pharma to showcase POLB 001 at leading scientific and investor conferences 3 September 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has been selected to present at a number of leading international conferences this September. […]

Read more

Resolution Therapeutics partners with the Blood Centers of America, Inc. to support broad patient access to its experimental Regenerative Macrophage Therapy in the U.S.

/in

Partnership will support Resolution’s pivotal clinical program in 2027, as well as future commercial preparedness for RTX001, its lead asset in patients with end-stage liver disease (ESLD) Primary goal is to ensure patients can access treatment in the community setting, where the majority of decompensated patients are managed RTX001 has the potential to be the […]

Read more
© Optimum Strategic Communications.